Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis

This network meta-analysis of 41 studies suggests that the concentrated formulation of insulin glargine (Gla-300) is linked to a lower risk of nocturnal hypoglycaemia compared with NPH and premixed insulin, with glycaemic control comparable to available basal insulin comparators.

A well-recognised limitation of any network meta-analyis is that, by design, these are not randomised comparisons; however, these data can aid the decision-making process until prospective randomised comparative clinical trial data become available.

 

High-strength insulin products such as insulin glargine 300 units/ml (Toujeo) have been developed for people with type 1 or type 2 diabetes who have large daily insulin requirements to reduce the number and volume of injections. NICE has issued an evidence summary for high-strength insulin glargine 300 units/ml (Toujeo) for type 2 diabetes mellitus in adults.

 

NICE has also issued guidance on insulin-based treatments in their guideline on the management of type 2 diabetes in adults.